Accéder au contenu
Merck

M5571

Miltefosine

≥98% (perchloric acid titration)

Synonyme(s) :

Choline hexadecyl phosphate, HePC, Hexadecyl phosphocholine

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

Toutes les photos(3)

About This Item

Formule empirique (notation de Hill) :
C21H46NO4P
Numéro CAS:
58066-85-6
Poids moléculaire :
407.57
NACRES:
NA.85
PubChem Substance ID:
329818017
UNSPSC Code:
51191904
MDL number:
MFCD00133396

Nom du produit

Miltefosine, ≥98% (perchloric acid titration)

InChI

1S/C21H46NO4P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-20-25-27(23,24)26-21-19-22(2,3)4/h5-21H2,1-4H3

SMILES string

[O-]P(OCC[N+](C)(C)C)(OCCCCCCCCCCCCCCCC)=O

InChI key

PQLXHQMOHUQAKB-UHFFFAOYSA-N

biological source

synthetic (organic)

description

zwitterionic

assay

≥98% (perchloric acid titration)

form

powder

solubility

H2O: 10 mg/mL, clear, colorless

functional group

phospholipid

lipid type

phospholipids

storage temp.

room temp

Quality Level

200

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Application


  • Easy one-pot synthesis of multifunctionalized indole-pyrrole hybrids as a new class of antileishmanial agents.: This study underlines the necessity for innovative treatments amidst growing resistance to established drugs such as miltefosine which is used as a positive control reference, potentially setting a new direction for antileishmanial drug development (Ciccone et al., 2024).

Biochem/physiol Actions

Inhibitor of protein kinase C and of phosphatidylcholine synthesis. Used for the treatment of visceral and cutaneous leishmaniasis. Active against metronidazole-resistant and -susceptible strains of Trichomonas vaginalis

pictograms

Skull and crossbones
GHS06

signalword

Danger

hcodes

H301

Hazard Classifications

Acute Tox. 3 Oral

Classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number
0000493667
0000493667
0000496706
0000496706
0000496707

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Rechercher un(e) COA

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Suresh K Tipparaju et al.
Journal of medicinal chemistry, 51(23), 7344-7347 (2008-11-08)
The first synthesis and biological evaluation of antibiotic 31 (A-33853) and its analogues are reported. Initial screening for inhibition of L. donovani, T. b. rhodesiense, T. cruzi, and P. falciparum cultures followed by determination of IC(50) in L. donovani and
Maria V Papadopoulou et al.
Journal of medicinal chemistry, 54(23), 8214-8223 (2011-10-26)
A series of novel 2-nitro-1H-imidazole- and 3-nitro-1H-1,2,4-triazole-based aromatic and aliphatic amines were screened for antitrypanosomal activity and mammalian cytotoxicity by the Drugs for Neglected Diseases initiative (DNDi). Out of 42 compounds tested, 18 3-nitro-1,2,4-triazoles and one 2-nitroimidazole displayed significant growth
Abdullah Alotaibi et al.
Scientific reports, 9(1), 11364-11364 (2019-08-08)
Extracts of 35 samples of European propolis were tested against wild type and resistant strains of the protozoal pathogens Trypanosoma brucei, Trypanosoma congolense and Leishmania mexicana. The extracts were also tested against Crithidia fasciculata a close relative of Crithidia mellificae
Nathan P Wiederhold et al.
Antimicrobial agents and chemotherapy, 57(2), 745-750 (2012-11-21)
Miltefosine is an alkyl phosphocholine with good oral bioavailability and in vitro activity against Cryptococcus species that has gained interest as an additional agent for cryptococcal infections. Our objective was to further evaluate the in vivo efficacy of miltefosine in
Thomas P C Dorlo et al.
Antimicrobial agents and chemotherapy, 52(8), 2855-2860 (2008-06-04)
The pharmacokinetics of miltefosine in leishmaniasis patients are, to a great extent, unknown. We examined and characterized the pharmacokinetics of miltefosine in a group of patients with Old World (Leishmania major) cutaneous leishmaniasis. Miltefosine plasma concentrations were determined in samples
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique